Cerus Co. (NASDAQ:CERS - Get Free Report) CEO William Mariner Greenman sold 23,023 shares of Cerus stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $1.55, for a total transaction of $35,685.65. Following the transaction, the chief executive officer now directly owns 3,230,000 shares of the company's stock, valued at $5,006,500. This represents a 0.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Cerus Trading Down 1.3 %
NASDAQ CERS traded down $0.02 during mid-day trading on Friday, reaching $1.51. 1,867,261 shares of the stock were exchanged, compared to its average volume of 1,505,992. Cerus Co. has a one year low of $1.38 and a one year high of $2.54. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The stock has a market cap of $280.54 million, a P/E ratio of -13.73 and a beta of 1.56. The stock has a 50 day simple moving average of $1.74 and a 200-day simple moving average of $1.79.
Cerus (NASDAQ:CERS - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting the consensus estimate of ($0.01). Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. The firm had revenue of $50.81 million during the quarter, compared to the consensus estimate of $50.81 million. On average, analysts anticipate that Cerus Co. will post -0.08 EPS for the current year.
Wall Street Analysts Forecast Growth
Separately, Cantor Fitzgerald reissued an "overweight" rating and set a $4.00 target price on shares of Cerus in a research note on Friday, February 21st.
Check Out Our Latest Stock Analysis on Cerus
Institutional Investors Weigh In On Cerus
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its stake in Cerus by 1.2% in the fourth quarter. Bank of New York Mellon Corp now owns 485,797 shares of the biotechnology company's stock valued at $748,000 after purchasing an additional 5,721 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in Cerus by 3.3% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 209,246 shares of the biotechnology company's stock valued at $322,000 after purchasing an additional 6,633 shares in the last quarter. Invesco Ltd. increased its stake in Cerus by 8.3% in the fourth quarter. Invesco Ltd. now owns 86,787 shares of the biotechnology company's stock valued at $134,000 after purchasing an additional 6,665 shares in the last quarter. Creative Planning increased its stake in Cerus by 51.3% in the third quarter. Creative Planning now owns 24,809 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 8,411 shares in the last quarter. Finally, Rhumbline Advisers increased its position in shares of Cerus by 3.7% during the fourth quarter. Rhumbline Advisers now owns 238,795 shares of the biotechnology company's stock worth $368,000 after acquiring an additional 8,458 shares in the last quarter. 78.37% of the stock is owned by institutional investors.
Cerus Company Profile
(
Get Free Report)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Further Reading
Before you consider Cerus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cerus wasn't on the list.
While Cerus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
